{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/phase-1b-studies-speed-vs-success-what-should-small-biotechs-weigh-moving-patients#webpage",
"url": "https://www.fortrea.com/insights/phase-1b-studies-speed-vs-success-what-should-small-biotechs-weigh-moving-patients",
"name": "Phase 1b studies. Speed vs. success: What should small biotechs weigh up before moving to patients?",
"description": "This Fortrea article explores how emerging biotech companies can accelerate Phase 1b clinical development by combining strategic planning, operational agility, and efficient trial execution. Early-phase studies often operate under significant timeline pressures as sponsors seek to generate clinical data, reach development milestones, and advance promising therapies into later-stage research. The article examines key factors that influence development speed, including study start-up planning, site activation, patient enrollment strategies, operational decision-making, and cross-functional collaboration. It also highlights how proactive clinical development approaches can help sponsors navigate common challenges associated with early-phase research while maintaining momentum toward clinical objectives. By aligning operational execution with development priorities, emerging biotech companies can improve efficiency, reduce delays, and create a stronger foundation for long-term clinical success."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Phase 1b studies. Speed vs. success: What should small biotechs weigh up before moving to patients?",
"item": "https://www.fortrea.com/insights/phase-1b-studies-speed-vs-success-what-should-small-biotechs-weigh-moving-patients"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry - as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/phase-1b-studies-speed-vs-success-what-should-small-biotechs-weigh-moving-patients#article",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/phase-1b-studies-speed-vs-success-what-should-small-biotechs-weigh-moving-patients#webpage"
},
"headline": "Phase 1b Clinical Development: Strategies for Accelerating Early-Phase Trials and Achieving Clinical Success | Fortrea Article",
"description": "This Fortrea article explores how emerging biotech companies can accelerate Phase 1b clinical development by combining strategic planning, operational agility, and efficient trial execution. Early-phase studies often operate under significant timeline pressures as sponsors seek to generate clinical data, reach development milestones, and advance promising therapies into later-stage research. The article examines key factors that influence development speed, including study start-up planning, site activation, patient enrollment strategies, operational decision-making, and cross-functional collaboration. It also highlights how proactive clinical development approaches can help sponsors navigate common challenges associated with early-phase research while maintaining momentum toward clinical objectives. By aligning operational execution with development priorities, emerging biotech companies can improve efficiency, reduce delays, and create a stronger foundation for long-term clinical success.",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2026-03/phase-1b-biotech-study.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2026-03-24",
"dateModified": "2026-03-24",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2026-03/phase-1b-biotech-speed-success.pdf",
"encodingFormat": "application/pdf"
}
}
]
}